Literature DB >> 8960826

Protein C activation in NIDDM patients.

E C Gabazza1, H Takeya, H Deguchi, Y Sumida, O Taguchi, K Murata, K Nakatani, Y Yano, M Mohri, M Sata, T Shima, J Nishioka, K Suzuki.   

Abstract

Enhanced activation of the clotting system has been recently implicated in the pathogenesis of vascular complications in patients with diabetes mellitus. Abnormalities of the anticoagulant system may constitute a potential trigger factor for the haemostatic activation observed in diabetic subjects. The current study aimed to evaluate anticoagulant activity in diabetic patients by assessing the plasma levels of activated protein C-protein C inhibitor complex; and by measuring the anticoagulant response to exogenous thrombomodulin. This study comprised 61 patients (34 men, 27 women) with non-insulin-dependent diabetes mellitus (NIDDM) of whom 22 showed microalbuminuria and 39 normoalbuminuria. Data obtained in 31 non-obese and non-diabetic subjects were available for comparison. The plasma levels of fibrinogen (p < 0.02), prothrombin fragment 1 + 2 (p < 0.05), fibrin monomer (p < 0.0001), protein C antigen (p < 0.005), total protein S antigen (p < 0.02), soluble thrombomodulin (p < 0.005) and soluble E-selectin (p < 0.005) were significantly higher in diabetic patients than in healthy subjects. The plasma level of activated protein C-protein C inhibitor complex (7.4 +/- 3.8 vs 3.0 +/- 0.4 pmol/l) was significantly higher (p < 0.0001) and the anticoagulant response to exogenous thrombomodulin (23.4 +/- 2.6 vs 35.3 +/- 3.0 ng/ml) was markedly lower (p = 0.005) in all diabetic patients than in healthy subjects. Cases with microalbuminuria presented low plasma levels of activated protein C-protein C inhibitor complex (5.5 +/- 0.6 vs 8.6 +/- 0.7 pmol/l, p < 0.05) and significantly decreased values of the anticoagulant response to exogenous thrombomodulin (16.5 +/- 2.9 vs 23.4 +/- 2.6%, p = 0.03) as compared to those with normoalbuminuria. The present study suggests that the hyper-coagulable state in NIDDM is associated with an increased activation of protein C but with a poor plasma reactivity to the anticoagulant effect of thrombomodulin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8960826     DOI: 10.1007/s001250050598

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  8 in total

1.  An examination of the association between therapeutic anticoagulation control and glycemic control for patients with diabetes on oral anticoagulation therapy.

Authors:  Samuel G Johnson; Daniel M Witt; Thomas Delate; Melanie A Sadler
Journal:  J Thromb Thrombolysis       Date:  2005-06       Impact factor: 2.300

2.  Hemostatic Factors, APOL1 Risk Variants, and the Risk of ESRD in the Atherosclerosis Risk in Communities Study.

Authors:  Adrienne Tin; Morgan E Grams; Nisa M Maruthur; Brad C Astor; David Couper; Thomas H Mosley; Myriam Fornage; Rulan S Parekh; Josef Coresh; Wen Hong Linda Kao
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-17       Impact factor: 8.237

3.  Role of activated protein C in Helicobacter pylori-associated gastritis.

Authors:  S Oka; E C Gabazza; Y Taguchi; M Yamaguchi; S Nakashima; K Suzuki; Y Adachi; I Imoto
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

4.  Visceral obesity and hemostatic profile in patients with type 2 diabetes: the effect of gender and metabolic compensation.

Authors:  Elzbieta Kozek; Barbara Katra; Maciej Malecki; Jacek Sieradzki
Journal:  Rev Diabet Stud       Date:  2004-11-10

5.  Urinary albumin excretion is correlated to fibrinogen levels and protein S activity in patients with type 1 diabetes mellitus without overt diabetic nephropathy.

Authors:  Zoltán Lengyel; Péter Vörös; Lajos K Tóth; Csilla Németh; László Kammerer; Mária Mihály; László Tornóci; László Rosivall
Journal:  Wien Klin Wochenschr       Date:  2004-04-30       Impact factor: 1.704

6.  Association of D-dimer with microalbuminuria in patients with type 2 diabetes mellitus.

Authors:  Ichiro Wakabayashi; Hiroshi Masuda
Journal:  J Thromb Thrombolysis       Date:  2007-10-11       Impact factor: 2.300

7.  Treatment of chronic diabetic lower leg ulcers with activated protein C: a randomised placebo-controlled, double-blind pilot clinical trial.

Authors:  Kaley Whitmont; Kelly J McKelvey; Gregory Fulcher; Ian Reid; Lyn March; Meilang Xue; Alan Cooper; Christopher J Jackson
Journal:  Int Wound J       Date:  2013-07-15       Impact factor: 3.315

8.  Effective INR Level May Be Delayed in Secondary Prevention of Stroke Due to Atrial Fibrillation with Warfarin in the Patients with Diabetes Mellitus.

Authors:  Türkan Acar; Yeşim Güzey Aras; Sıdıka Sinem Gül; Bilgehan Atilgan Acar
Journal:  Noro Psikiyatr Ars       Date:  2018-10-24       Impact factor: 1.339

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.